STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy | Aplastic Anemia & MDS International Foundation
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Clinical Trial: NCT03063944

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This phase I trial studies the side effects and best dose of STAT inhibitor OPB-111077 when given together with decitabine and venetoclax in treating patients with acute myeloid leukemia that does not respond to treatment or is newly diagnosed and ineligible for intensive chemotherapy. STAT inhibitor OPB-111077, decitabine and venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
 

Status: 
Recruiting
Study Date: 
Fri, 02/24/2017 to Wed, 11/01/2023
Bone Marrow Disease(s): 
  • acute myeloid leukemia (AML)
Associated Drug(s): 
Intervention: 
Drug: STAT Inhibitor OPB-111077 Given PO Other Name: OPB-111077 Drug: Decitabine Given IV Other Names: 127716 2'-Deoxy-5-azacytidine 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one 2353-33-5 Dacogen Deoxyazacytidine Drug: Venetoclax Given PO